SCHEMBL7148472

SCHEMBL7148472

COc1ccc(OC)c(S(=O)(=O)N(c2ccccc2)C2CCN(Cc3ccccc3)CC2)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.64
ALDH1A1 P00352 5/20 0.55
MAPK1 P28482 1/20 0.55
SIGMAR1 Q99720 3/20 0.51
CHRM2 P08172 1/20 0.51
CHRM3 P20309 1/20 0.51
CCR3 P51677 1/20 0.48
PKM P14618 1/20 0.48
ACHE P22303 5/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 1/20 0.48
DRD2 P14416 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
BACE1 P56817 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142628 0.84 KMT2A (0.62) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7149783 0.84 ACHE (0.54) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7141686 0.82 CHRM2 (0.61) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7164480 0.82 ACHE (0.55) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7167334 0.81 ALDH1A1 (0.52) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7167826 0.80 ALDH1A1 (0.55) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7166030 0.79 CHRM2 (0.57) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7165839 0.79 CHRM2 (0.57) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7257312 0.78 ALDH1A1 (0.56) KMT2AALDH1A1MAPK1SIGMAR1CHRM2
SCHEMBL7166368 0.78 ALDH1A1 (0.52) KMT2AALDH1A1MAPK1SIGMAR1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 KMT2A 1833/4885ALDH1A1 1218/4885MAPK1 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.